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in the Right Direction
Nehal N. Mehta1 and Joel M. Gelfand2,3,4
There is epidemiological evidence that high-density lipoprotein (HDL) concentra-
tions, or HDL ‘‘levels,’’ exert protection from atherosclerosis, suggesting that HDL
plays a role in vascular diseases. More accurate measures of HDL ‘‘function’’ are
emerging, such as HDL efflux assays, which measure removal of cholesterol from
peripheral tissues. Using this assay, we have demonstrated that psoriasis is
associated with decreased HDL ‘‘levels’’ and HDL ‘‘function.’’ The study by Holzer
et al. in this issue demonstrates in an open-label, uncontrolled study that HDL
function is impaired in psoriasis and improves after successful treatment of
psoriasis. These findings underscore the notion that treatment of psoriasis likely
extends beyond the skin and that a randomized controlled clinical trial is needed
to confirm these findings.
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Several lines of evidence have demon-
strated that psoriasis, a chronic T-
helper cells 1 and 17 inflammatory skin
disease, is associated with systemic
inflammation (Mehta et al., 2011),
metabolic diseases (Azfar et al., 2012;
Langan et al., 2012; Armstrong et al.,
2013), predisposition to cardiovascular
(CV) risk factors (Neimann et al., 2006),
and cardiovascular disease (Gelfand
et al., 2006; Mehta et al., 2010;
Armstrong et al., 2012; Yeung et al.,
2013). Indeed, these lines of evidence
span from basic cellular models (Nestle
et al., 2009), animal models (Davidovici
et al., 2010), and observational human
studies (Mehta et al., 2013). The
weight of the evidence, mechanist-
ically, biologically, and epidemiologi-
cally, support the notion that systemic
inflammation, either induced experi-
mentally in humans or that what is
observed in psoriasis, is associated
with a heightened state of CV risk.
What factors may play roles in
increasing CV risk for patients with
psoriasis? Indeed, conventional CV risk
factors such as hypertension, tobacco
use, obesity, and diabetes are more
prevalent in psoriasis, but the associa-
tion with CV outcomes persists even
after adjusting for these factors in large,
population-based studies (Gelfand et al.,
2006; Ahlehoff et al., 2011; Langan
et al., 2012; Li et al., 2012). Further-
more, dyslipidemia, defined by the
conventional assessment of lipids, has
been shown to be increased in psoriasis
(Ma et al., 2013) and, most recently,
triglycerides were found to be increased
in a dose-dependent manner with
increasing body surface areas affected
by psoriasis, independent of the usual
risk factors, such as body mass index
(Langan et al., 2012). Lipid panels
usually rely on direct concentration
measurements of total cholesterol, high-
density lipoproteins (HDLs), and trigly-
cerides, with calculation to estimate
low-density lipoproteins (LDLs). How-
ever, these metrics have variable res-
ponses to antipsoriatic treatments,
despite a large body of preclinical and
human evidence demonstrating that
induction of inflammation worsens
HDL levels in humans (McGillicuddy
et al., 2009; de la Llera Moya et al.,
2012). Furthermore, it would be expec-
ted that with improvements in known
CV markers and direct measurement
of vascular inflammation following
open-label antipsoriatic treatment
(Bissonnette et al., 2013) lipids, namely
HDL, would improve; however, in these
studies this relationship was observed
inconsistently. These findings reinforce
the idea that changes in HDL chole-
sterol levels are an inadequate surrogate
for responses to therapy (Schwartz et al.,
2012) and that more precise techniques
to understand cholesterol composition
and function are needed (Rosenson
et al., 2012). These new measures
include lipid particle size and number
measured by nuclear magnetic res-
onance spectroscopy, which provides
an assessment of the composition of
the lipid content beyond concentration
alone (Jeyarajah et al., 2006). These
metrics predicted first myocardial
infarction within a prospective popu-
lation-based study with equivalent
performance as LDL concentration
(Mora et al., 2009). In psoriasis, lipid
particle size and number have also been
demonstrated to be more atherogenic in
a study of 100 patients (Mehta et al.,
2012b) and also associated with vas-
cular inflammation (Yu et al., 2012).
Conventional lipid measures in these
patients were ‘‘normal,’’ including
HDL levels. However, the function of
HDL cholesterol, which performs a
process called ‘‘reverse cholesterol
transport’’ (RCT), was impaired in
psoriasis as well (Mehta et al., 2012b).
This pathway involves efflux of chole-
sterol from macrophages (such as those
within atherosclerotic plaque) to HDL
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acceptor particles for ultimate return to
the liver and biliary excretion. HDL
efflux is thought to be a central func-
tion that makes HDL the ‘‘good’’
cholesterol (Khera et al., 2011). In fact,
recent studies demonstrate that raising
HDL pharmacologically is not protective
against CV events, most likely because
these approaches do not improve HDL
function (Schwartz et al., 2012; Khera
et al., 2013). Thus, developing new
approaches to target the HDL pathway
to lower CV risk is an area of intense
scientific and medical interest.
In this issue, Holzer et al. (2014)
followed up on a previous observation
that HDL efflux is abnormal in psoriasis
(Holzer et al., 2012) by performing an
open-label study of psoriasis treatment
to understand the effect on HDL
characteristics. HDL was isolated from
15 patients with moderate to severe
psoriasis at baseline and after effective
topical and/or systemic antipsoriatic
therapy; they were compared with 15
age- and sex-matched controls. HDL
efflux was measured using two
validated techniques: (1) by depleting
serum of all apolipoprotein B–
containing lipids, and (2) by isolating
HDL directly, using centrifugation tech-
niques. Other known important charac-
teristics of HDL such as HDL
phospholipid content and enzymatic
mediators within the RCT pathway,
including HDL paraoxanase and lipo-
protein-associated phospholipase A2
(Lp-PLA2), were also measured before
and after therapy. The investigators con-
firmed earlier observations that HDL
efflux was reduced in patients, consis-
tent with the hypothesis that increased
systemic inflammation impairs the RCT
pathway (Holzer et al., 2012; Mehta
et al., 2012b). They also observed,
after 56–100 weeks of treatment, that
the reduction in Psoriasis Area and
Severity Index (PASI) scores was asso-
ciated with improvement in HDL efflux
from isolated HDL. Furthermore, sup-
porting the notion of improvement in
HDL characteristics, paraoxonase and
Lp-PLA2 enzyme activity were modu-
lated in a favorable direction. The
authors also reported that there was an
increase in HDL size by nuclear mag-
netic resonance, suggesting that phos-
pholipid content increased within the
HDL, also supporting the observation
that HDL characteristics were more
favorable after successful treatment of
psoriasis. Finally, all of these improve-
ments in HDL function and composition
occurred, despite the lack of change in
blood lipid levels and including HDL.
These findings are largely consistent
with earlier observations in healthy
humans that experimental inflammation
in vivo modulates HDL function and
composition (McGillicuddy et al., 2009;
Mehta et al., 2009; de la Llera Moya
et al., 2012). Our group has demon-
strated that HDL efflux decreases after
administration of lipopolysaccharide
(LPS), a known stimulator of innate
immune pathways known to be
activated in psoriasis. Furthermore, in
that study, LPS led to a decrease in HDL
phospholipid content, and this correla-
ted highly with HDL efflux. Holzer et al.
(2014) extend these findings by
demonstrating that HDL phospholipid
was reduced in psoriasis compared
with healthy controls and that this
content tended to improve following
successful treatment. Furthermore,
the increase in lecithin–cholesterol
acyltransferase activity suggests that
cholesterol esterfication improved
following therapy, which would
facilitate exit of cholesterol from the
body. However, these findings must be
interpreted with caution. The authors do
not provide free cholesterol and
cholesterol ester data before and after
therapy, which are more precise
measures of lecithin–cholestrol
acyltransferase activity (Vaisman and
Remaley, 2013). Moreover, the small
sample size, lack of a randomized
placebo controlled design, and inabi-
lity to determine which specific treat-
ment improved HDL function all remain
to be addressed.
The strengths of the study are that
authors used rigorous lab methods to
provide the initial characterization of
treatment effects on HDL properties in
patients with psoriasis. The study brings
to center stage the concept that the
conventional methods of assessing CV
risk in psoriasis may be in need of
refinement (Mehta et al., 2012a). This
concept of residual risk for CV disease,
despite improvement in the usual risk
factors, suggests use of newly developed
functional measures. Furthermore, there
are still limited data on whether
treatment of psoriasis will improve
outcomes for CV disease or for the risk
factors alone. Another small open-label
study demonstrated in humans that
treatment of psoriasis utilizing anti-
tumor necrosis factor (anti-TNF)
therapy led to improvement in carotid
intimal-medial thickness, a surrogate
marker of CV disease (Jokai et al.,
2013). However, whether improvement
in such surrogate markers would hold
up under a more rigorous randomized,
placebo-controlled trial design and
ultimately translate into improvement
in CV outcome is unknown. This app-
roach of utilizing a validated surrogate
marker to understand whether there is
improvement in an outcome was widely
used in earlier studies of lipid treatment,
using rigorous randomized controlled
trials (Taylor et al., 2009). Reduction in
cholesterol levels as well as improve-
ment in imaging of atherosclerosis
served as proxies for lower CV out-
comes. However, if psoriasis is in the
causal pathway for CV diseases (i.e., an
Clinical Implications
 Recent studies demonstrate that raising high-density lipoprotein (HDL)
pharmacologically is not protective of cardiovascular (CV) events likely
because these approaches do not improve HDL function (Schwartz et al.,
2012; Khera et al., 2013).
 Developing new approaches to targeting the HDL pathway to lower CV
risk is an area of intense scientific and medical interest.
 The results by Holzer et al. (2014) in this issue may be a step in the right




intermediate risk factor), a strategy to
tease out disease treatment effects on
CV outcomes will require concomitant
use of surrogate end points as well as
outcome studies to understand how
treatment modulates short- and long-
term CV risk.
A strategy currently underway to
advance understanding of CV risk, treat-
ment effects, and outcomes in psoriasis
includes performance of a randomized,
placebo-controlled trial of psoriasis
treatment (anti-TNF, UVB therapy,
and placebo) with a primary outcome
of vascular inflammation by fluoro-




NCT01866592), a novel imaging bio-
marker that measures CV risk for both
short-term (Fayad et al., 2011) and long-
term events (Arauz et al., 2007;
Rominger et al., 2009). However,
larger simple trials studying CV
outcomes in psoriasis such as those
currently underway in nonpsoriasis
patients evaluating the effect of very
low dose methotrexate in patients with
cardiovascular disease (Ridker, 2009)
will also need to be planned. Until
then, we can certainly gain insight
from this and other recent studies that
suggest that successful treatment of
inflammation in vivo leads to improv-
ement in cardiometabolic diseases
(Maki-Petaja et al., 2012), the most
potent source of mortality in psoriasis.
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Inflammasome Activation by
Propionibacterium acnes: The Story of
IL-1 in Acne Continues to Unfold
Diane M. Thiboutot1
Insights into the immune mechanisms at play in skin diseases including acne
continue to be made. In this issue, Kistowska et al. confirm that Propionibacter-
ium acnes activates inflammasomes leading to the production of IL-1b and they
further identify putative mechanisms by which this process occurs. These data
raise interesting questions regarding a multipronged approach by which P. acnes
elicits inflammation in early versus late acne and putative differences in the effects
of IL-1a and IL-1b in this disease process.
Journal of Investigative Dermatology (2014) 134, 595–597. doi:10.1038/jid.2013.528
Propionibacterium acnes is the predo-
minant organism in the microbiome of
facial skin (Grice et al., 2009). Although
thought to be commensal, P. acnes
exerts a variety of pro-inflammatory
activities most notable in patients with
acne vulgaris. This intriguing organism
orchestrates a multipronged approach to
trigger innate immunity in acne by
activating toll-like receptor 2 and, as
reported now, inflammasomes (Kim
et al., 2002; Kistowska et al., 2014;
Qin et al., 2014).
As reported in this issue, remarkable
convergence with respect to inflamma-
some activation by P. acnes has been
achieved (Kistowska et al., 2014; Qin
et al., 2014). Kistowska et al. (2014)
present a series of elegant experiments
that confirm and expand upon the
recent seminal findings of Qin et al.
(2014). Using a combination of in vitro
and in vivo assays, including inflamma-
some activation in monocytes, immuno-
histochemistry of inflammatory acne
lesions from patients, a mouse ear
model for P. acnes-induced inflam-
mation, and transgenic mouse models
of several defects in the inflammasome
pathway, Kistowska et al. (2014) con-
firm that P. acnes induces inflamma-
some activation in human monocytes
that is mediated by NLRP3 leading to
cleavage of pro-IL-1b to active IL-1b via
caspase 1. The authors demonstrate that
the release of IL-1b by monocytes in
response to P. acnes requires
phagocytosis, lysosomal damage with
release and activation of cathepsin B,
generation of reactive oxygen species,
and Kþ efflux as pointed out in their
recent commentary (Contassot and
French, 2014). Furthermore, they pro-
pose that IL-1b secreted from myeloid
cells in a NLRP3-inflammasome-depen-
dent manner, is responsible for the
induction of a neutrophilic inflamma-
tory response to P. acnes in vivo
(Kistowska et al., 2014).
In view of these advances, it becomes
even more compelling to examine how
and where P. acnes interacts with
immune cells (including keratinocytes)
in the distinct microenvironments of
early versus late acne lesions. This
question is relevant clinically in that
understanding the pro-inflammatory
actions of P. acnes in very early acne
may aid in identifying targets to suppress
early inflammation and thus to avoid
intensification of the inflammatory
response that follows follicular rupture.
Kistowska et al. (2014) injected P. acnes
into the dermis of the mouse ear to
model late stage acne. In the dermis,
P. acnes may be phagocytised by
myeloid cells, leading to inflamma-
some activation, secretion of IL-1b and
a neutrophilic response (Kistowska
et al., 2014). They conclude that mye-
loid cells are key players in inflamma-
some activation in acne.
In early acne, however, follicles are
surrounded by an infiltrate of lympho-
cytes and macrophages, and P. acnes is
contained within the intact follicle in
proximity to follicular keratinocytes
(Layton et al., 1998; Jeremy et al.,
2003). Very little is known about the
dynamics of myeloid cell infiltration
into follicles at this early stage. Toyoda
and Morohashi, (2001) published
electron micrographs depicting macro-
phages in close proximity to follicular
keratinocytes, but whether these were
early or late lesions and whether the
follicles were intact or disrupted were
not specified. Neutrophils were noted to
infiltrate the follicles and reach the
cornified layers, but it is uncertain
whether these neutrophils interacted
with P. acnes contained within the
follicles (Toyoda and Morohashi,
2001).
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